Vor Biopharma (VOR) AI Stock Analysis

• Market Cap: $237.32M
• Dividend Yield: N/A
• Average Volume (3M): 250.09K
• Price to Earnings (P/E): ―
• Beta (1Y): 4.26
• Revenue Growth: N/A
• EPS Growth: -686.12%
• Country: US
• Employees: 159
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.26
• Shares Outstanding: 6,841,134
• 10 Day Avg. Volume: 366,193
• 30 Day Avg. Volume: 250,085
• PEG Ratio: 0.23
• Price to Book (P/B): 0.79
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.76
• Enterprise Value/Market Cap: >-0.01
• Enterprise Value/Revenue: -0.01
• Enterprise Value/Gross Profit: 0.02
• Enterprise Value/Ebitda: <0.01
• 1Y Price Target: $29.00
• Price Target Upside: -14.23% Downside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 33 Underperform
• Price Target: ―

Vor Biopharma faces significant financial challenges, with no revenue and ongoing losses. Technical indicators suggest weak market sentiment, and the lack of positive valuation metrics further underscores the risk. Investors should be cautious due to the high financial risk and uncertainty.

Positive Factors

Strategic Collaborations

Successful collaboration with RemeGen in a Phase 3 study highlights Vor Biopharma's ability to form strategic partnerships, enhancing its pipeline and potential market reach.

Innovative Technology

Vor Biopharma's focus on eHSCs technology positions it at the forefront of cancer treatment innovation, potentially leading to safer and more effective therapies.

Pipeline Development

The company's robust pipeline targeting hematologic malignancies suggests strong future growth potential as these therapies progress through clinical trials.

Negative Factors

Financial Strain

Ongoing financial losses and lack of revenue generation pose significant risks to Vor Biopharma's long-term viability, necessitating external funding to sustain operations.

Leadership Changes

The resignation of the Chief Medical Officer may disrupt strategic continuity and impact the company's ability to advance its clinical programs effectively.

Cash Flow Challenges

Persistent negative cash flow reflects operational inefficiencies and reliance on external funding, which could hinder long-term sustainability and growth.

Vor Biopharma Business Overview & Revenue Model

Company Description

Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

How the Company Makes Money

Vor Biopharma generates revenue primarily through research and development collaborations, partnerships, and potential future product sales. The company's business model is centered around developing its pipeline of eHSC-based therapies, which are designed to improve the efficacy and safety of existing cancer treatments. Revenue streams may include milestone payments and royalties from strategic partnerships with larger pharmaceutical companies, as well as potential licensing agreements for its proprietary technologies. Additionally, Vor Biopharma may secure funding through government grants or research institutions to support its innovative research initiatives.

Vor Biopharma Financial Statement Overview

Summary

Vor Biopharma demonstrates significant financial strain, with no revenue generation and consistent net losses. The company's balance sheet shows declining equity, and cash flow statements reflect ongoing cash burn problems. These factors collectively point to high financial risk and uncertainty about future viability.

Income Statement

Vor Biopharma has consistently reported zero revenue, indicating a lack of operational income generation. The company has been operating at a loss for several years, with negative EBIT and net income, highlighting significant profitability challenges.

Balance Sheet

The company maintains a moderate debt-to-equity ratio, which suggests limited leverage. However, the continuous decline in stockholders' equity and total assets since 2020 raises concerns about financial stability and sustainability.

Cash Flow

Vor Biopharma's free cash flow has been consistently negative, indicating cash burn issues. The operating cash flow is also negative, suggesting operational inefficiencies and an inability to cover costs without external funding.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	3.69M	0.00	0.00	0.00	0.00	0.00
Gross Profit	-1.98M	-3.53M	-3.49M	-8.96M	-4.45M	-1.39M
EBITDA	-365.68M	-113.39M	-114.37M	-90.89M	-67.58M	-41.95M
Net Income	-1.66B	-116.91M	-117.86M	-90.77M	-68.78M	-43.34M
Balance Sheet
Total Assets	205.37M	142.89M	198.13M	299.37M	242.59M	75.91M
Cash, Cash Equivalents and Short-Term Investments	200.56M	91.93M	137.18M	230.25M	207.47M	48.54M
Total Debt	0.00	31.83M	35.66M	38.91M	18.01M	18.29M
Total Liabilities	1.71B	46.23M	47.40M	48.76M	26.33M	27.64M
Stockholders Equity	-1.51B	96.66M	150.72M	250.61M	216.26M	48.27M
Cash Flow
Free Cash Flow	-114.09M	-99.89M	-101.36M	-93.61M	-73.04M	-40.45M
Operating Cash Flow	-113.60M	-99.66M	-100.29M	-85.14M	-69.14M	-36.29M
Investing Cash Flow	310.00K	96.86M	71.01M	-94.09M	-91.65M	-4.16M
Financing Cash Flow	227.79M	53.39M	2.94M	117.14M	232.91M	82.53M

Vor Biopharma Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 33.81
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VOR, the sentiment is Positive. The current price of 33.81 is below the 20-day moving average (MA) of 35.21, below the 50-day MA of 39.44, and above the 200-day MA of 23.86, indicating a neutral trend. The MACD of -2.22 indicates Positive momentum. The RSI at 46.59 is Neutral, neither overbought nor oversold. The STOCH value of 65.05 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VOR.

Vor Biopharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SNTI	47 Neutral	36.89M	-0.16	―	―	-100.00%	29.21%
ZNTL	46 Neutral	109.65M	-0.65	―	―	-33.76%	17.10%
CCCC	44 Neutral	172.23M	-1.38	-48.76%	―	16.55%	16.73%
ELUT	43 Neutral	44.52M	-0.97	50.95%	―	-5.22%	82.06%
PLRX	37 Underperform	89.63M	-0.42	―	―	―	-9.87%
VOR	33 Underperform	$237.32M	―	-125.43%	―	―	-686.12%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Vor Biopharma Corporate Events

Vor Biopharma’s Chief Medical Officer Resigns

On March 31, 2025, Eyal C. Attar, M.D., announced his resignation as Chief Medical Officer of Vor Biopharma Inc., effective April 18, 2025, to pursue a new opportunity. Vor Biopharma plans to enter into a consulting agreement with Dr. Attar for transition services, acknowledging his contributions to the company.

Vor Biopharma Approves Stock Option Repricing Strategy

On February 3, 2025, Vor Biopharma’s board approved a stock option repricing to reduce the exercise price of certain options to $1.34 per share, impacting approximately 6.76 million shares. This move aims to motivate and retain employees while avoiding stock dilution or additional cash outlays, with a retention period set until February 3, 2026 or earlier under specific conditions.